Ultrasound contrast developer Point Biomedical has raised $27.1 million from private equity financing.
The San Carlos, CA-based vendor said it would use the proceeds to file a new drug application (NDA) with the Food and Drug Administration for its Cardiosphere ultrasound imaging agent, which is designed for the assessment of myocardial perfusion in patients with coronary artery disease. Point also said it would retire debt related to construction of its commercial manufacturing facility.
By AuntMinnie.com staff writers
August 19, 2004
Copyright © 2004 AuntMinnie.com